These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 16784654)
21. [Methylation status of FHIT gene in plasma and expression of FHIT gene in cancer tissue of cervical cancer patients]. Ren CC; Miao XH; Yang B; Zhao L; Sun R; Song WQ Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Oct; 23(5):565-7. PubMed ID: 17029211 [TBL] [Abstract][Full Text] [Related]
22. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation. Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840 [TBL] [Abstract][Full Text] [Related]
23. Alterations of the FHIT gene in human hepatocellular carcinoma. Yuan BZ; Keck-Waggoner C; Zimonjic DB; Thorgeirsson SS; Popescu NC Cancer Res; 2000 Feb; 60(4):1049-53. PubMed ID: 10706123 [TBL] [Abstract][Full Text] [Related]
24. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328 [TBL] [Abstract][Full Text] [Related]
25. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Yeo W; Wong N; Wong WL; Lai PB; Zhong S; Johnson PJ Liver Int; 2005 Apr; 25(2):266-72. PubMed ID: 15780049 [TBL] [Abstract][Full Text] [Related]
26. Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis. Nan KJ; Ruan ZP; Jing Z; Qin HX; Wang HY; Guo H; Xu R World J Gastroenterol; 2005 Jan; 11(2):228-31. PubMed ID: 15633221 [TBL] [Abstract][Full Text] [Related]
27. Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma. Lu B; Ma Y; Wu G; Tong X; Guo H; Liang A; Cong W; Liu C; Wang H; Wu M; Zhao J; Guo Y Clin Cancer Res; 2008 Nov; 14(22):7405-12. PubMed ID: 19010857 [TBL] [Abstract][Full Text] [Related]
28. Hypermethylation of the 5'CpG island of the FHIT gene in clear cell renal carcinomas. Kvasha S; Gordiyuk V; Kondratov A; Ugryn D; Zgonnyk YM; Rynditch AV; Vozianov AF Cancer Lett; 2008 Jul; 265(2):250-7. PubMed ID: 18378390 [TBL] [Abstract][Full Text] [Related]
29. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development. Lea JS; Ashfaq R; Muneer S; Burbee DG; Miller DS; Minna JD; Muller CY J Soc Gynecol Investig; 2004 Jul; 11(5):329-37. PubMed ID: 15219888 [TBL] [Abstract][Full Text] [Related]
30. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients. Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757 [TBL] [Abstract][Full Text] [Related]
31. Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Wang J; Qin Y; Li B; Sun Z; Yang B Clin Biochem; 2006 Apr; 39(4):344-8. PubMed ID: 16527261 [TBL] [Abstract][Full Text] [Related]
32. Inverse correlation of aberrant expression of fragile histidine triad (FHIT) protein with cyclin D1 protein and prognosis in Chinese patients with cholangiocarcinoma. Zhao P; Lu Y; Zhong M; Liu L; Li B Acta Oncol; 2008; 47(8):1557-63. PubMed ID: 18618300 [TBL] [Abstract][Full Text] [Related]
33. [The relationship between FHIT and WWOX expression and clinicopathological features in hepatocellular carcinoma]. Lin J; Wang B; Huang AM; Wang XJ Zhonghua Gan Zang Bing Za Zhi; 2010 May; 18(5):357-60. PubMed ID: 20510001 [TBL] [Abstract][Full Text] [Related]
34. Promoter hypermethylation of the p16 gene is associated with poor prognosis in recurrent early-stage hepatocellular carcinoma. Ko E; Kim Y; Kim SJ; Joh JW; Song S; Park CK; Park J; Kim DH Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2260-7. PubMed ID: 18723830 [TBL] [Abstract][Full Text] [Related]
35. Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepatocellular carcinoma. Lu CY; Hsieh SY; Lu YJ; Wu CS; Chen LC; Lo SJ; Wu CT; Chou MY; Huang TH; Chang YS Genes Chromosomes Cancer; 2009 Dec; 48(12):1057-68. PubMed ID: 19760608 [TBL] [Abstract][Full Text] [Related]
36. Aberrant methylation of the CHFR gene in advanced hepatocellular carcinoma. Sakai M; Hibi K; Kanazumi N; Nomoto S; Inoue S; Takeda S; Nakao A Hepatogastroenterology; 2005; 52(66):1854-7. PubMed ID: 16334792 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of Relationship between Occurrence of Liver Cancer and Methylation of Fragile Histidine Triad (FHIT) and P16 Genes. Bai Y; Shen Y; Yuan Q; Lv C; Xing Q Med Sci Monit; 2019 Feb; 25():1301-1306. PubMed ID: 30773529 [TBL] [Abstract][Full Text] [Related]
38. Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis. Kitamura K; Hayashi K; Kobayashi R; Ishii H; Matsubayashi J; Matsumoto T; Suzuki M Oncol Rep; 2008 Apr; 19(4):847-52. PubMed ID: 18357366 [TBL] [Abstract][Full Text] [Related]
39. Frequent promoter methylation of M-cadherin in hepatocellular carcinoma is associated with poor prognosis. Yamada S; Nomoto S; Fujii T; Takeda S; Kanazumi N; Sugimoto H; Nakao A Anticancer Res; 2007; 27(4B):2269-74. PubMed ID: 17695513 [TBL] [Abstract][Full Text] [Related]
40. Genetic polymorphisms of methylenetetrahydrofolate reductase and promoter methylation of MGMT and FHIT genes in diffuse large B cell lymphoma risk in Middle East. Siraj AK; Ibrahim M; Al-Rasheed M; Bu R; Bavi P; Jehan Z; Abubaker J; Murad W; Al-Dayel F; Ezzat A; El-Solh H; Uddin S; Al-Kuraya K Ann Hematol; 2007 Dec; 86(12):887-95. PubMed ID: 17712558 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]